Physician profile
Robert M Smith
NPI 1538113337
$1,990.95
in general payments reported to CMS, 2019-2025
17 companies · $490 in 2025
The $490 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $295 · 2021: $443 · 2024: $237 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $727.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $380.73 | 2021-2025 | Xolair, Perjeta, Phesgo |
| Astrazeneca Pharmaceuticals Lp | $340.50 | 2019-2025 | Tezspire |
| Csl Behring | $322.59 | 2019-2021 | |
| Genzyme Corporation | $191.77 | 2019-2025 | |
| Glaxosmithkline, LLC. | $140.51 | 2019-2025 | Nucala |
| Ars Pharmaceuticals Operations, INC. | $122.98 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $90.81 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $88.74 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $82.42 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.44 | 2019-2021 | |
| Biocryst Pharmaceuticals, INC. | $58.57 | 2020 | |
| Novartis Pharmaceuticals Corporation | $20.40 | 2019 | |
| Cycle Pharmaceuticals INC | $19.02 | 2025 | Sajazir |
| Uswm, LLC | $16.00 | 2021 | |
| Shire North American Group INC | $15.79 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $15.00 | 2025 | Dawnzera |
| Pharming Healthcare, INC. | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.